Flash Sell: Book 250% Gains Right Now

By Ray BlancoPosted February 21, 2020

Space tourism hit a new milestone. A new space ship is ready for testing in the Mojave desert. And your open position has gone parabolic. Let’s grab these gains while we still can…

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication(s) below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Ray Blanco’s VIP Tech Advantage

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Internet of Things Taking off, Rare Disease Developer on a Roll, Plus Two Sells

By Ray BlancoPosted November 7, 2014

The Internet of Things is expected to be the next big thing in tech. Bigger than the personal computer, bigger than the original Internet and bigger than the smartphone. And the IoT revolution is picking up steam. That's great news for the company up in July-- an IoT pure play...

An Emerging VR Powerhouse That Beat the Street — With Much More to Come

By Ray BlancoPosted February 19, 2016

Late last year, I talked to you about the new world of virtual reality and the fortunes it will make. I also predicted 2016 would become the breakout year when VR tech starts to go mainstream. So far, it looks like we've knocked it out of the park.

Updates: Exelixis and ARM

By Ray BlancoPosted November 3, 2011

There can be many twists and turns for a powerful new cancer drug before it finally makes it to market, where it can save lives. This week, the FDA denied Exelixis a special protocol assessment (SPA) for its clinical-stage cancer drug, cabozantinib, for metastatic prostate cancer. Basically, an SPA is where the FDA tells a company that a clinical trial's design, clinical endpoints and statistical analysis will be "good enough" for FDA approval ahead of time.

Updates: DragonWave and Seattle Genetics

By Ray BlancoPosted July 15, 2011

Dips create opportunities to accumulate a favorable position in some really good emerging technology companies. With the current environment being what it is, a number of them are still below our buy price targets, and will appreciate as their technology enters the market.

Despite Crash, Self-Driving Cars Going Mainstream Soon

By Ray BlancoPosted July 1, 2016

Our cars will soon become some of the most powerful computing devices we own... and they will use that power to take us safely where we want to go. This will be the biggest change in ground transportation since the invention of the automobile. And our recent recommendation is at the very center of the revolution.

Space is Looking Up!

By Ray BlancoPosted March 13, 2020

Even though the coronavirus has rocked the markets… space technology continues to look up. At SATELLITE 2020 I had the opportunity for face-to-face meetups with several companies. Giving me incredible insight into the industry and where we’ll be in the coming years.

Login